United Therapeutics Corp (FRA:UTH)
€ 245.3 4.6 (1.91%) Market Cap: 10.88 Bil Enterprise Value: 8.92 Bil PE Ratio: 12.50 PB Ratio: 2.19 GF Score: 89/100

United Therapeutics Corp at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 15, 2022 / 01:20PM GMT
Release Date Price: €159 (+0.63%)
Hartaj Singh
Oppenheimer & Co. Inc., Research Division - Research Analyst

Thank you, Ben. Really appreciate it. Always really good work to make it so easy for us. Hey, everybody. We have today for our first day of the Oppenheimer Healthcare Conference, one of the companies I have been following for a long time called United Therapeutics. Their Chief Financial Officer, James; and Patrick, Head of Technical Ops, if I'm not mistaken. Sorry, if I give you a promotion, Patrick, or maybe not. But we have both of them joining us today for a conversation.

So both of you, welcome. And James, maybe you could start off with about a 3- to 5-minute state-of-the-business intro. But really appreciate having both of you here.

James C. Edgemond
United Therapeutics Corporation - CFO & Treasurer

Yes. Good morning, Hartaj. Really first, I want to thank you for inviting us to the fireside chat this morning and Oppenheimer for the opportunity to join the conference now, as I mentioned, but also throughout the day.

And before I jump into it, Hartaj, let

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot